Ginkgo biloba Extract Prescriptions Are Associated with Slower Progression of Dementia Severity-Analysis of Longitudinal Real-World Data - PubMed

3 min read Original article ↗

Ginkgo biloba Extract Prescriptions Are Associated with Slower Progression of Dementia Severity-Analysis of Longitudinal Real-World Data

Jens Bohlken et al. Brain Sci. .

Abstract

Background/objectives: Previous research indicates that Ginkgo biloba extract (Gbe) may contribute to slowing down the progression of dementia. This retrospective cohort study analyzed the association between Gbe prescriptions and the progression of dementia severity in a real-world setting.

Methods: This study was conducted using data from patients with an initial diagnosis of mild or moderate dementia between January 2005 and December 2022 from the IQVIA™ Disease Analyzer database. The follow-up period was up to 10 years. The association between Gbe prescription and dementia severity progression was assessed by Kaplan-Meier analysis and Cox regression, with adjustments made for age, sex, health insurance status, physician specialty, co-prescription of antidementia drugs, and co-diagnoses.

Results: A total of 4765 patients were included, of whom 177 were prescribed Gbe. The cumulative incidence of dementia severity progression was 12.7% for patients with Gbe prescription and 22.1% for those without. Gbe prescription was associated with a significantly decreased risk of dementia severity progression (hazard ratio: 0.50; 95% CI: 0.27-0.95), both in patients with mild (HR: 0.44; 95% CI: 0.22-0.90) and moderate dementia (HR: 0.24; 95% CI: 0.06-0.98).

Conclusions: This study provides evidence that Gbe prescription is associated with a reduced risk of dementia severity progression in a real-world setting.

Keywords: Alzheimer’s disease; Ginkgo biloba extract; cognitive impairment; dementia; phytomedicine; retrospective study.

PubMed Disclaimer

Conflict of interest statement

K.K. is an employee of IQVIA, Frankfurt a. M., Germany. J.B. received honoraria for consultancy from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. M.B. is a full-time employee of Schwabe Holding, Karlsruhe, Germany. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Dr. Willmar Schwabe GmbH & Co. KG., Karlsruhe, Germany. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Figures

Figure 1
Figure 1

Selection of patients.

Figure 2
Figure 2

Cumulative incidence of dementia progression in patients with mild and moderate dementia.

Figure 3
Figure 3

Cumulative incidence of dementia progression in patients with and without Gbe prescription.

References

    1. Bradfield N.I. Mild Cognitive Impairment: Diagnosis and Subtypes. Clin. EEG Neurosci. 2023;54:4–11. doi: 10.1177/15500594211042708. - DOI - PubMed
    1. Komarova N.L., Thalhauser C.J. High degree of heterogeneity in Alzheimer’s disease progression patterns. PLoS Comput. Biol. 2011;7:e1002251. doi: 10.1371/journal.pcbi.1002251. - DOI - PMC - PubMed
    1. Carroll C.M., Benca R.M. Upsetting the Balance: How Modifiable Risk Factors Contribute to the Progression of Alzheimer’s Disease. Biomolecules. 2024;14:274. doi: 10.3390/biom14030274. - DOI - PMC - PubMed
    1. Blotenberg I., Hoffmann W., Thyrian J.R. Dementia in Germany: Epidemiology and Prevention Potential. Dtsch. Arztebl. Int. 2023;120:470–476. doi: 10.3238/arztebl.m2023.0100. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Global Action Plan on the Public Health Response to Dementia 2017–2025. WHO; Geneva, Switzerland: 2017.

LinkOut - more resources